Warfarin is an oral anticoagulant widely prescribed for a variety of thromboembolic indications including venous thromboembolism (VTE), deep vein thrombosis (DVT) and the prevention of stroke associated for atrial fibrillation (AF) [1] . Warfarin requires ongoing monitoring of Internationalised Normalised Ratio (INR) due to a narrow therapeutic index and interactions with numerous drugs [2] . The time in therapeutic range (TTR) is often used to indicate the quality of warfarin therapy due to the established correlation between higher mean TTR and reduced complications such as bleeding and thromboembolism [3] . TTR is strongly associated with bleed risk, but increased bleeding with warfarin has also been associated with patient comorbidities and concurrent administration of other medication linked to bleeding including antiplatelet agents and non-steroidal anti-inflammatories (NSAIDs) [4] .
There is a high prevalence of patients on warfarin prescribed concurrent therapy with clinically relevant warfarin drug interactions [5] . Snaith et al. [6] . reported 68% of patients prescribed warfarin are issued a prescription for a potentially interacting drug, with long-term NSAIDs and lowdose aspirin prescribed to 21% and 17% of warfarinized patients, respectively. Higher rates of concurrent warfarin and aspirin use of 30%-40% were reported in the large comparative trials of warfarin and the non-vitamin K oral antagonists in patients with non-valvular AF [7] [8] [9] . Combination therapy with warfarin and antiplatelet agents may be indicated for specific subsets of patients with mechanical heart valve replacement and low bleed risk [10, 11] . However, Turan et al. [12] . reported the warfarin-aspirin combination being used inappropriately in around 21% of their AF patients on chronic warfarin therapy. Similarly, Schaefer et al. [13] . found over one-third of their patients are treated with warfarin together with aspirin for AF and/or VTE without a clear indication and associated this combination with a significant increase in major and non-major bleeding. Shireman et al. [14] . found that after adjusting for other risk factors, the combination of warfarin and antiplatelet therapy resulted in a 50% increased risk of a major bleed event.
An increased risk of bleeding from drug interactions with warfarin may occur due to additive effects, such as with aspirin or antiplatelet agents, or due to changes in warfarin absorption or metabolism [15] . The NSAIDs can have an antiplatelet action but selected NSAIDs including the cyclooxygenase-2 (COX-2) inhibitors can also alter warfarin levels through direct interaction with warfarin metabolism [16] . Hauta-Aho et al. [17] . demonstrated no change to INR values when the interacting drugs only affected platelet function but found significantly higher INR values in patients receiving inhibitors of cytochrome (CYP) 2C9. Similar to this, Choi et al. [18] . showed that almost 40% of patients on warfarin had an INR increase after initiation of a NSAID with the highest risk from meloxicam and lower risk from naproxen, celecoxib and ibuprofen. In contrast, Turck et al. [19] . showed no significant change in INR with warfarin and meloxicam and similarly Dentali et al. [20] . found co-administration of celecoxib did not significantly affect warfarin control as measured by INR. Thus, there is conflicting evidence on the effect of NSAIDs on warfarin control and the majority of literature available focusses on INR levels as opposed to overall control as measured by TTR. Therefore, the aim of this study was to determine the impact on warfarin control as measured by TTR and bleeds by the co-administration of NSAIDs including aspirin and COX-2 inhibitors. private pathology practice in Queensland and receiving warfarin therapy for AF or DVT. Data including age, gender, current medications, comorbidities, INR test results, reported thromboembolic events and bleeds were collected. This information was used to group patients into those taking NSAIDs or not taking NSAIDs. The Australian Medicines Handbook [21] was utilized to identify concurrent medications that interact with warfarin, and patients on these medications were excluded so patients on no other interacting drugs and taking NSAIDs or not taking NSAIDs were further analysed. Patients taking NSAIDs were further subcategorized into groups taking aspirin, NSAIDs (excluding aspirin), COX-2 selective inhibitors (celecoxib and meloxicam) and NSAIDs (excluding COX-2 selective inhibitors and aspirin).
INR results were used to calculate TTR using the Rosendaal method [22] from the INR Pro© Patient Anticoagulation Software. To be eligible for the study, a minimum of two INR tests and 30 days of INR testing was required. HASBLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile International Normalised Ratio or INR, Elderly >65 years, Drugs/alcohol concomitantly) score was calculated to assess bleed risk. Bleeds were categorized and calculated based on a per person basis and compared between the groups. Bleeding was categorized in accordance with standardized definitions [23] , namely: (1) major bleeding included bleeding into critical areas or major organs such as: gastrointestinal bleeding and included clinically relevant bleeds requiring diagnostic testing, any form of hospitalization or intervention by a healthcare professional; (2) minor bleeding included bleeds such as nose bleeds that were not clinically relevant and required no intervention, no hospitalization and no medical attention.
Mean and standard deviation were utilized to report age with number and percentages used for gender, comorbidities, NSAID medications and bleed risk scores. GraphPad InStat version 3 (GraphPad Software, Inc., La Jolla, CA, USA) was used to analyse the data with a p-value <0.05 considered to be statistically significant. Patients on NSAIDs versus patients not on NSAIDs were compared using the Mann-Whitney test. Patients that were not on NSAIDs versus individual NSAIDs were analysed using the Kruskal-Wallis test (nonparametric ANOVA). Statistical significance was calculated for individual NSAIDs through Dunn's multiple comparisons test. The MedCalc comparison of proportions calculator was used to compare minor bleeding and major bleeding of patients on NSAIDs to those not on NSAIDS.
Results
A total of 4494 patients were included in the study with the majority (70.6%) not taking NSAIDs ( fig. 1 ). There was no statistical difference between the mean age of patients on NSAIDs (75.7 AE 10.5 years) and not on NSAIDs (76.2 AE 11.6 years). Approximately 70% of patients were between the ages of 70-89 years old (table 1) . There was approximately the same number of males and females in the study, with the dominating comorbidity being atrial fibrillation followed by hypertension. The most commonly prescribed NSAID was aspirin (56.7%) followed by celecoxib (7.5%) and ibuprofen (7.3%).
Before excluding interacting drugs with warfarin, there was a statistically significant difference in TTR for patients on NSAIDs compared with no NSAIDs (78.9 AE 9.7% versus 80.9 AE 10.2%, respectively, p < 0.0001). After excluding all interacting drugs with warfarin, there was a significantly lower TTR (p = 0.0080) in patients taking NSAIDs (80.2 AE 10.3%) compared with those not taking NSAIDs (82.0 AE 11.2%) (table 2). Patients taking aspirin alone had a significantly reduced (p = 0.0488) TTR of 80.4 AE 10.3% when compared with patients not taking NSAIDS (82.0 AE 11.2%). No significant difference was found in TTR when other groups of NSAIDs, including the COX-2 selective NSAIDs, were compared to TTR of patients not taking NSAIDs. No significant differences were found in the frequency of testing for patients on NSAIDs compared with no NSAIDs before or after excluding for interacting drugs (14.5 AE 4.5 versus 15.5 AE 5.1 days and 15.6 AE 4.7 versus 16.4 AE 5.4 days, respectively).
Patients taking NSAIDs (excluding aspirin) had significantly more major and minor bleeding events than those not taking NSAIDS (p = 0.0391 and p = 0.0359, respectively). Compared to patients not taking NSAIDs, the use of aspirin alone significantly increased minor bleeding but had no significant difference in major bleed events. There was no significant difference in bleed events with the COX-2 selective NSAIDs.
Discussion
Several variables can affect warfarin control including patientspecific factors such as concurrent medications. Concurrent medications may affect warfarin by increasing the risk of bleeding or interfering with warfarin metabolism, with some medication reported to do both such as selected NSAIDs. An increased risk of bleeding with NSAIDs has been reported, but there is limited data on the effect on warfarin control, particularly as measured by TTR. The aim of this study was to determine the impact on warfarin control as measured by TTR by the concurrent administration of NSAIDs, particularly aspirin and COX-2 inhibitors. This study found aspirin significantly reduced TTR and was associated with an increase in minor bleeds, whilst the COX-2 inhibitors did not significantly affect TTR or events with warfarin.
Patients on any NSAIDs had significantly different TTRs than patients not on NSAIDs; however, when categorized according to agent prescribed, it was only patients on aspirin with significantly decreased TTR of around 2%. Similar to this, Williams et al. [24] . recently found aspirin to be a strong predictor of TTR and proposed predicting a decrease of around 5% TTR for newly initiated warfarin patients on aspirin. Interestingly, Bernaitis et al. [25] . found antiplatelet agents reduced TTR in a Singapore population with poorer control (mean TTR 58%) but did not affect TTR in an Australian population with high control (mean TTR 82%). Further to this, Okumura et al. [26] . found TTR was not affected by co-administration of antiplatelet drugs in a Japanese population. The reduced TTR with aspirin is particularly noteworthy given the high level of warfarin control in this study, namely a mean above 80%. This study was conducted in a dedicated warfarin programme which has been shown to have particularly good warfarin control and levels above other management models, such as by general practitioners, which are more around the standard 70% TTR [27] . A limitation of this study is that sub-analyses could not be performed in patients with good and poor control as only 13% of patients with no other interacting drugs had a TTR < 70% (data not shown). However, a strength of this study compared to the previously mentioned two studies [25, 26] analysing TTR in patients on antiplatelet agents is that our study removed all other potentially interacting drugs and this could explain the difference in findings. Similarly, whilst studies have reported conflicting evidence regarding potentially no change [19, 20] or an increase in INR [18] with COX-2 inhibitors, in this study, there was no change in TTR for patients taking COX-2 inhibitors. This study investigated long-term control as measured by TTR, and thus, whilst changes in INR may have occurred, the overall TTR may not have been affected with COX-2 inhibitors but was with aspirin alone. Further investigation of doses involved for both warfarin and the individual NSAIDs is warranted to determine the potential impact on doses and potential adjustments to warfarin which may have also impacted TTR in these patients.
There was a higher percentage of minor bleeding in patients who were on NSAIDs compared to those not on NSAIDs and when categorized according to NSAID involved, aspirin alone significantly increased minor bleeding events. Similarly, Proietti and Lip [28] found that poor anticoagulation control (TTR < 65%) was associated with higher bleeding risk, which was even greater with concomitant aspirin use. In this study, despite a high TTR of over 80%, aspirin users had a higher rate of minor bleeding and thus bleeds were less likely to be due to poor anticoagulant control but more likely to be due to additive effects with aspirin. Numerous studies have reported increased risk of major bleeding with warfarin and aspirin [13, 14] . Further to this, Battistella et al. [29] . demonstrated an increased risk of upper gastrointestinal bleeding with both selective COX-2 inhibitors and non-selective NSAIDs. In contrast to these findings, our study found no significant difference in major bleeds with aspirin alone or with the COX-2 inhibitors. Prostaglandin inhibition may be the main mechanism of damage to the upper gastrointestinal mucosa but other risk factors include older age, history of ulcer or H. pylori infection [30] and lower doses of aspirin may have greater effects on thromboxane than prostaglandin inhibition [31] . Therefore, it is likely that whilst NSAIDs decrease production of prostaglandins, including the GI protective ones, aspirin is debatably less likely to do this which may explain the non-significant difference in major bleed events seen with aspirin users and the significantly higher major bleeding seen with NSAIDs excluding aspirin. It was also unexpected that there was no increase in major bleeds with aspirin and NSAIDs given the HASBLED score of these patients was a median of two points higher than those not on NSAIDs. The concurrent use of NSAIDs automatically adds one point to HASBLED, but the median of 3 in patients taking NSAIDs and aspirin also suggests the presence of another comorbidity that would place a patient at increased risk of bleeding which may contribute to explaining the increase in minor bleeds. However, the greatest impact on these findings is the limitation that as with all retrospective studies, bleeding was self-reported and detailed information was not provided for all events which may have impacted on the event number and categorization. Future prospective investigations should include specific data on bleed location, INR at the time of bleed and subsequent impact on TTR according to bleed events.
Conclusion
In conclusion, this study found that patients on aspirin had significantly more reduced TTRs than patients not on aspirin with an associated increase in minor bleeds. Whilst previous studies have identified the concern regarding increased bleeds due to additive effects with warfarin, there may also be a decreased level of warfarin control as measured by TTR associated with concurrent aspirin use warranting further caution and monitoring of the combination. 
